Elevance Health, Inc (ELV)
Key Takeaways:
Company Overview
Elevance Health, Inc. is one of the largest U.S. managed care companies, serving about 45.2 million medical members through a mix of risk-based insurance, self-funded administration, and healthcare services. Its core portfolio spans commercial, Medicare, Medicaid, and Federal Employee Program coverage, with a strong Blue Cross and Blue Shield footprint across multiple large states. The company also owns Carelon, which includes pharmacy benefit services, specialty pharmacy, care management, behavioral health, post-acute support, and data/analytics-enabled services. This gives Elevance a more integrated model than a traditional insurer, but also exposes it to execution risk, regulatory scrutiny, and reimbursement pressure. The business is heavily tied to government programs and policy changes, with roughly one-third of revenue linked to U.S. government agencies. Recent results show strong top-line growth, but margin pressure from rising medical costs, Medicaid redeterminations, and higher operating complexity. The company’s scale, brand, and provider network are meaningful assets, yet the model remains vulnerable to pricing missteps, star-rating volatility, pharmacy regulation, and litigation risk.
Business Segments
Economic Moat Analysis
Elevance Health has a real competitive position, but not a fortress-like one. Its strongest moat sources are the BCBS brand, large provider networks, and scale in government programs. Those assets help it compete, especially in local and employer markets, and they create moderate barriers to entry. However, the moat is constrained by the economics of managed care: pricing is reset frequently, regulation is intrusive, employers and states are price-sensitive, and competitors can still win business through lower bids or better quality scores. Carelon improves the moat by adding integrated pharmacy and care services, but the company still faces substantial regulatory, political, and reimbursement risk. Overall, the moat is best described as narrow rather than wide.
The Blue Cross and Blue Shield brands remain a major competitive asset in many local markets and are especially valuable for large employer accounts.
Extensive provider networks and BlueCard reach create meaningful consumer and employer value, especially across multi-state coverage needs.
Deep operating experience in Medicaid, Medicare, and ACA products creates know-how that newer entrants often lack, but it is not fully protective because rules can change quickly.
Employers, states, and members face some friction in changing plans, but healthcare coverage remains price-sensitive and switchable at renewal.
Carelon’s pharmacy and care-management capabilities can improve retention and economics, though rivals are also building similar integrated platforms.
Clinical, claims, and pharmacy data can support underwriting and care management, but data advantages are less durable in a heavily regulated industry than in software-like businesses.
Key Strengths
- Scale Advantage: The company operates at very large national scale, with broad membership and diversified revenue streams across commercial, government, and pharmacy-related services.
- Brand Positioning: Exclusive and long-standing Blue Cross and Blue Shield licenses in major states provide strong brand recognition and local market credibility.
- Integrated Care Model: Carelon ties together pharmacy, behavioral health, care management, and analytics, which can improve coordination and help contain costs.
- Provider Network: Large provider access and BlueCard reach support product competitiveness, especially for multi-state employer groups and traveling members.
- Diversified Mix: Revenue is spread across Health Benefits, CarelonRx, and Carelon Services, reducing dependence on any single product line.
- Capital Flexibility: Investment-grade debt ratings, sizable liquidity, and access to credit facilities support ongoing operations and capital returns.
- Government Expertise: Deep experience in Medicaid, Medicare Advantage, and FEP contracts creates operational know-how that is difficult for smaller rivals to replicate.
Identified Weaknesses
- Margin Pressure: Rising medical cost trends are compressing Health Benefits profitability and have already reduced operating gain despite revenue growth.
- Government Dependence: A large portion of revenue comes from Medicare, Medicaid, and federal programs, leaving the company exposed to policy and funding changes.
- Complex Operations: The business spans insurance, PBM, care delivery, and analytics, increasing execution risk and raising the chance of operational inefficiency.
- Regulatory Burden: Heavy state and federal oversight limits pricing flexibility, affects product design, and can delay strategic actions.
- Medicaid Volatility: Membership fell meaningfully due to redeterminations, highlighting the sensitivity of earnings to eligibility changes and state-level dynamics.
- Litigation Exposure: Blue Cross Blue Shield litigation and other disputes create recurring financial and reputational risk.
- High Intangibles: Goodwill and intangible assets are very large relative to equity, increasing balance-sheet vulnerability if acquired assets underperform.
Growth Opportunities
- Carelon Expansion: Growth in care management, post-acute care, behavioral health, and analytics could improve mix and deepen customer relationships.
- Medicare Advantage Growth: Medicare Advantage membership and improved star ratings offer a path to better enrollment and possible quality bonuses.
- Specialty Pharmacy: Rising utilization of specialty drugs supports demand for integrated pharmacy management and infusion services.
- Value-Based Care: More provider contracts tied to outcomes could improve cost control and create stickier relationships with health systems.
- Digital Engagement: Tools like Sydney Health and HealthOS can improve consumer experience, data exchange, and administrative efficiency.
- Public Exchange Growth: Expansion into additional Exchange geographies can add membership, though with elevated pricing and morbidity risk.
- Operational Leverage: If medical cost trend stabilizes, scale could translate into better expense leverage and stronger margins.
Risk Factors
- Medical Inflation: Higher inpatient, outpatient, pharmacy, and labor costs can outpace pricing and damage margins quickly.
- Policy Risk: Medicaid redeterminations, ACA subsidy changes, Medicare pricing reforms, and PBM regulation could materially alter economics.
- Star Rating Risk: Medicare Advantage bonus economics depend on CMS ratings, which can shift due to methodology changes and quality performance.
- Competitive Pressure: Large national insurers, regional plans, PBMs, retailers, and digital-first entrants continue to pressure pricing and retention.
- Provider Consolidation: Hospitals and physician groups have more bargaining power, which can raise reimbursement rates or reduce network access.
- Cybersecurity Risk: The company handles highly sensitive health data and depends on complex IT systems, making breaches a major operational and legal threat.
- Interest Rate and Credit Risk: Elevated rates can raise borrowing costs and reduce the value of the investment portfolio.
- Reputation Risk: Negative public sentiment toward insurers, prior authorization, and pharmacy practices can trigger stricter regulation and member attrition.
Valuation Metrics
Price multiples: P/E 17.28 and Forward P/E 13.15 indicate the market expects earnings growth (forward multiple meaningfully below trailing). This is generally supportive for both value (reasonable earnings yield) and growth (expectations are positive).
Growth-adjusted valuation: PEG 3.51 is high versus what’s typically desired (often ~1–2). This suggests that relative to the growth rate, the stock may not be cheap—more aligned with a ‘moderate value / not-stressed’ rather than deep value entry.
Sales and cash-flow multiples: P/S 0.42 is low, implying the company trades at a conservative price-to-sales level. P/FCF is missing, but P/C 1.88 and P/S together suggest valuation is not rich on revenue.
Book valuation: P/B 1.52 with ROE 0.23% (see profitability). Because ROE looks extremely low, a higher P/B than expected would be a concern, but note the ROE figure may be distorted by accounting or balance-sheet effects; still, pure value based on book is less reliable here.
Enterprise multiples: EV/EBITDA 13.41 and EV/Sales 6.27 are mixed—EBITDA multiple looks reasonable, but EV/Sales is elevated versus the low P/S. This can happen due to high enterprise value adjustments and/or leverage structure (also consistent with the missing EV in the dataset).
Cash per share is 0.69 (Cash/sh 0.69). With Book/sh 206.99, book value is dominated by accounting net assets rather than liquid cash. Valuation support should therefore come mainly from earnings/operating margins rather than cash coverage.
Earnings & Profitability
Profitability strength (from margins): Gross Margin 64% and Oper. Margin 20.33% are strong for a managed healthcare model. Profit Margin 10.92% is solid, indicating earnings power beyond pure gross profitability.
Return metrics show mixed signals: ROA 0.34% and ROE 0.23% are extremely low relative to the margins shown. This mismatch suggests either (a) balance-sheet denominators are very large (e.g., working capital, regulatory/liability structure), (b) accounting effects depress ROA/ROE, or (c) data inconsistency. Still, margin profitability looks healthy, so the business economics may be better than ROA/ROE imply.
ROIC 4.28% is moderate. For a compounder, you’d prefer higher and improving ROIC; however, 4% can be acceptable depending on capital intensity and stability.
Earnings growth indicators: EPS (ttm) 22.50, EPS next Y 29.57, and EPS next Q 4.66 suggest analysts expect forward acceleration. EPS Y/Y TTM is -10.31%, indicating recent softness even as forward expectations look better.
Quarterly trend: EPS Q/Q is -4.37% and Sales Q/Q is +6.27%, implying revenue is holding up while EPS is pressured (cost trend, mix, or one-offs may be at play).
Earnings/estimate behavior: EPS/Sales Surpr. 1.52 indicates some tendency to beat on sales/earnings metrics historically (directionally positive).
Overall profitability picture: strong operating and gross margins support quality; but the negative recent EPS Y/Y and low ROA/ROE mean you should focus on trend stability and forward EPS credibility rather than headline returns alone.
Growth Analysis
Forward growth: EPS next Y 29.57 vs EPS (ttm) 22.50 implies roughly +31% (back-of-envelope). That’s a strong growth expectation for a large, mature healthcare insurer.
Near-term uncertainty: EPS this Y 27.13 and EPS past 3/5Y is not fully specified; however, EPS past 3/5Y shows 8.84% / 3.75% (interpreting as past multi-year growth). This looks like mid-single-to-low growth historically, while next-year expectations are higher—could reflect normalization after a weak period.
Sales momentum: Sales Y/Y TTM 3.75% (positive) and Sales Q/Q +6.27% suggest revenue growth is present even if EPS is temporarily compressed.
Forward growth vs valuation tension: the PEG of 3.51 suggests either the market discounts some risks, or the growth rate implied by analyst estimates is not enough to justify multiples. For a growth investor, this is a key watch item—growth must materialize to justify the price.
Financial Health
Liquidity: Quick Ratio 1.27 and Current Ratio 6.99 indicate strong short-term liquidity and coverage.
Leverage: Debt/Eq 0.67 and LT Debt/Eq 0.68 suggest moderate leverage (not excessive). For an insurer/health services company, this is generally manageable if cash flow remains stable.
Balance-sheet structure appears equity-heavy given high book/sh and strong current ratio; however, the low ROE/ROA caution you that the accounting capital base may be large.
Short-term market risk (liquidity to trade): short float 4.26% and short interest 32.82% (and short ratio 4.28) indicate some positioning risk, but not extreme relative to typical large-cap dynamics.
Ownership Structure
Ownership: Insider Own 0.23% (low, typical for large caps). Insider Trans 0.34% suggests some activity but not heavy insider control.
Institutional ownership is strong: Inst Own 94.71%. This supports liquidity and suggests the stock is widely held by institutions.
Institutional flow: Inst Trans 2.47% indicates active institutional participation; without buy/sell direction, interpret cautiously, but high institutional ownership generally reduces idiosyncratic risk.
Market Performance
Trend vs moving averages: SMA20 388.82 and SMA50 392.73 and SMA200 447.86. Current Price 392.73 (from data) is near the 20/50-day range but still below the 200-day average—this reads as a medium-term consolidation / below long-term trend.
52-week range: 52W High 447.86 and 52W Low 392.73 (approx from provided). The current price appears near the lower end of the range, which can be constructive for value entries and risk-reward, but not a clear bullish signal.
Recent performance: Perf Week -2.44%, Perf Month -0.95%, Perf Quarter -6.58%, and Perf YTD -10.70%. This indicates a weak to corrective tape recently.
Longer-term: Perf 3Y +32.82% and Perf 5Y +210.29% with Perf 10Y -? (not provided). The longer horizon performance is very strong, consistent with a high-quality compounder, but current cycle looks temporarily challenged.
Momentum & Volatility
Volatility: Volatility 4.28 and ATR (14) 5.34 indicate moderate daily price movement for a mega-cap; risk is present but not extreme.
Beta: Beta 1.05 indicates slightly higher sensitivity than the market.
RSI: RSI (14) 43.47 suggests slightly bearish / not oversold. There may be room to re-rate if earnings stabilize, but it’s not a ‘panic’ oversold setup.
Relative volume: Rel Volume 1.25 with Avg Volume 5.34M and Volume 1.25M (from the dataset’s fields). This looks like below-average trading on the day cited, so conviction behind movement may be limited.
Short interest: Short Interest 2.47% and Short Float 4.26% with Short Ratio 4.28 indicates short interest exists. If fundamentals improve, there is potential for short-covering, but current short levels don’t scream ‘crowded short’.
Investment Recommendations
value Investor:
With P/E 17.28 and Forward P/E 13.15 plus current price near the lower end of the 52-week range, a reasonable value entry would be closer to a discount to current trading. Target roughly $375–$385 (about 2–5% below the near-52W low area) to improve margin of safety given recent -YTD performance and PEG 3.51.
growth Investor:
Because forward EPS is expected to rise (EPS next Y 29.57) but recent EPS Y/Y TTM is negative (-10.31%) and RSI is only mid-bearish, growth-style entries should wait for either (a) improved price confirmation or (b) a deeper pullback. Target roughly $380–$395, with preference for the lower end if earnings guidance is reaffirmed.
Investment Summary
ELV shows quality profitability (64% gross, 20% operating margin) and a favorable forward multiple (Forward P/E 13.15 vs P/E 17.28), supporting both styles. However, PEG 3.51 and recent EPS decline (EPS Y/Y TTM -10.31%) temper “cheap growth” expectations. Balance sheet liquidity is strong (Quick 1.27, Current 6.99). Value investors: consider entry ~$375–$385; growth investors: ~$380–$395 with earnings stabilization.